ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1719

Prevalence and Trajectory of Erosions, Synovitis, and Bone Marrow Edema in Feet of Patients with Early Rheumatoid Arthritis
Abstract Number: 1720

Factors Associated with an Increased Risk of Imminent Rheumatoid Arthritis in ACPA+ Individuals
Abstract Number: 1721

Increasing Autoantibody Positivity During Pre-RA Is Associated with the Imminent Development of Classifiable RA
Abstract Number: 1722

Predicting Rheumatoid Arthritis Using the Symptoms in Persons at Risk of Rheumatoid Arthritis (SPARRA) Questionnaire
Abstract Number: 1723

RA Flare Prediction via Machine Learning and Algorithm Based on SSDM Big Data
Abstract Number: 1724

A Feasible and Efficient Approach to Implementing Rheumatoid Arthritis Disease Activity Measure in a Busy Rheumatology Clinic: A Quality Improvement Project
Abstract Number: 1725

An Investigation of the Relationship Between Patient Reported Outcomes and Biomarkers in a Community Rheumatology Practice
Abstract Number: 1726

Assessment of the Components of RAPID3 Patient Reported Outcomes in an Community Rheumatology Practice
Abstract Number: 1727

Patterns of Fatigue in Early RA over 10 Years: Results from the ESPOIR Cohort
Abstract Number: 1728

Patient-Reported Outcomes of Upadacitinib versus Abatacept in Patients with Rheumatoid Arthritis and an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: 12-Week Results of a Phase 3 Study
Abstract Number: 1729

Associations Between Patient Reported Outcomes and Impairments of Work and Activity in Patients with Rheumatoid Arthritis Who Achieved Clinical Remission; Retrospective Analysis Using the IORRA Database
Abstract Number: 1730

Comparison of MBDA Score, Patient Global Assessment and Evaluator Global Assessment for Predicting Risk of Radiographic Progression
Abstract Number: 1731

Development of a Disease Activity Index for Rheumatoid Arthritis Patients Using the HandScan
Abstract Number: 1732

Machine Learning Coupled with Patient Reported Outcome Data to Classify & Predict RA Disease Activity
Abstract Number: 1733

Patients with Rheumatoid Arthritis and Comorbid Depression Have High Levels of RAPID3 (Routine Assessment of Patient Index Data) and FAST3 (Fibromyalgia Assessment Screening Index) on a Multidimensional Health Assessment Questionnaire (MDHAQ)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].